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Abstract
Background: Obesity at diagnosis is associated with poor prognosis in women with breast cancer, but few reports have been 
adjusted for treatment factors.
Methods: CALGB 9741 was a randomized trial of dose density and sequence of chemotherapy for node-positive breast 
cancer. All patients received doxorubicin, cyclophosphamide, and paclitaxel, dosed by actual body weight. Height and 
weight at diagnosis were abstracted from patient records, and the PAM50 assay was performed from archived specimens 
using the NanoString platform. Relationships between body mass index (BMI), PAM50, and recurrence-free and overall 
survival (RFS and OS) were evaluated using proportional hazards regression, adjusting for number of involved nodes, 
estrogen receptor (ER) status, tumor size, menopausal status, drug sequence, and dose density. All statistical tests were two-
sided.
Results: Baseline height and weight were available for 1909 of 2005 enrolled patients; 1272 additionally had subtype 
determination by PAM50. Median baseline BMI was 27.4 kg/m2. After 11 years of median follow-up, there were 619 RFS 
events and 543 deaths. Baseline BMI was a statistically significant predictor of RFS (adjusted hazard ratio [HR] for each five-
unit increase in BMI = 1.08, 95% confidence interval [CI] = 1.02 to 1.14, P = .01) and OS (adjusted HR = 1.08, 95% CI = 1.01 to 
1.14, P = .02) BMI and molecular phenotypes were independent prognostic factors for RFS, with no statistically significant 
interactions detected.
Conclusions: BMI at diagnosis was a statistically significant prognostic factor in a group of patients receiving optimally 
dosed chemotherapy. Additional research is needed to determine the impact of weight loss on breast cancer outcomes and 
to evaluate whether this impact is maintained across tumor subtypes.
Obesity is a well-established risk factor for poor prognosis in 
women with early-stage breast cancer (1–4). Several reviews 
and meta-analyses have summarized the many studies looking 
at the relationship between body weight at the time of breast 
cancer diagnosis and cancer outcomes in women with early-
stage disease. For example, a recent meta-analysis of 82 reports 
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on this topic reported a 34% increase in breast cancer–related 
mortality and a 41% increase in overall mortality in women who 
were obese at the time of breast cancer diagnosis as compared 
with women who were of normal weight (4).
Some controversy exists regarding the interaction between 
tumor hormone receptor status and the relationship between 
body weight and breast cancer prognosis. A recent report from 
the Early Breast Cancer Trialists Group evaluating the relation-
ship between body mass index (BMI) at diagnosis and breast 
cancer mortality in women with early-stage breast cancer 
participating in adjuvant therapy trials demonstrated a 34% 
increase in breast cancer mortality in obese premenopausal 
women with hormone receptor–positive cancer, but did not 
show any relationship between body weight and outcomes in 
women with hormone receptor–negative cancers (5). In contrast, 
a meta-analysis of 21 studies found no evidence of interaction 
by hormone receptor status on the relationship between obesity 
and outcomes (6).
The mechanisms underlying the relationship between BMI 
and prognosis in early breast cancer are not fully understood. 
Some reports have suggested that part of this excess in breast 
cancer mortality in obese women may arise because of differ-
ences in tumor biology, with obese women being more likely 
to develop high-grade or hormone receptor–negative tumors 
(7,8). Other work has focused on the role of treatment factors 
in mediating the relationship between body weight and can-
cer outcomes, given that obese patients have often received 
less aggressive or dose-reduced therapy in the adjuvant setting 
(9,10). Finally, translational work has demonstrated that meta-
bolic hormones and inflammatory mediators are linked to both 
obesity and breast cancer outcomes (11–14), suggesting putative 
pathways through which host factors could influence cancer 
growth and progression.
In order to overcome the adverse impact of obesity on out-
comes in early breast cancer, a better understanding of the fac-
tors driving the relationship between body weight and breast 
cancer outcomes is needed. We evaluated the relationship 
between body mass index and rates of breast cancer recurrence 
and all-cause mortality in patients who participated in Cancer 
and Leukemia Group B (CALGB) 9741, an adjuvant treatment 
trial for women with breast cancer that required weight-based 
dosing for all participants, regardless of BMI (15). Additionally, 
we evaluated the relationship between BMI and distribution of 
tumor subtypes, in order to provide better insight into whether 
obese patients developed tumors that were biologically more 
aggressive. Finally, given the conflicting data regarding the 
interaction between tumor hormone receptor status and the 
relationship between body weight and breast cancer prognosis, 
we explored the relationships among tumor subtype, BMI, and 
cancer recurrence.
Methods
The patient cohort for this study was taken from the study pop-
ulation of C9741 (15), a randomized trial testing the impact of 
chemotherapy drug sequence and dose density upon the risk of 
cancer recurrence in women with lymph node–positive breast 
cancer. All patients in C9741 received treatment with cyclo-
phosphamide, doxorubicin, and paclitaxel. The study used a 
two-by-two factorial design. The first factor was drug sequence 
(concurrent doxorubicin and cyclophosphamide followed by 
paclitaxel vs doxorubicin, followed by paclitaxel followed by 
cyclophosphamide), and the second factor was dose-density 
(treatment cycles every two weeks with growth factor support 
vs every three weeks). The study protocol mandated that all 
chemotherapy be dosed by actual body weight. The protocol 
suggested a five-year course of tamoxifen for all premenopausal 
women with estrogen receptor–positive breast cancer and for all 
postmenopausal women regardless of hormone receptor status. 
Eligibility criteria included the presence of at least one involved 
lymph node, absence of metastatic cancer, and diagnosis of 
breast cancer within the past 84 days.
The study was open to enrollment between September 1997 
and March 1999. The CALGB, Eastern Cooperative Oncology 
Group, Southwest Oncology Group, and North Central Cancer 
Treatment Group participated in the study (CALGB is now part 
of the Alliance for Clinical Trials in Oncology). All participants 
signed an institutional review board–approved, protocol-specific 
informed consent document meeting all federal and institu-
tional regulatory requirements.
Measures
Height and weight at the time of participant enrollment (after 
definitive surgery but before initiation of systemic therapy) 
were abstracted from patient study charts stored at the Alliance 
Statistics and Data Center. BMI was calculated according to 
the formula: BMI = weight (kg)/height (m)2. BMI categories were 
defined according to the World Health Organization as under-
weight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), over-
weight (25–29.9 kg/m2), and obese (BMI ≥ 30 kg/m2).
Verification of chemotherapy dosing was performed to ensure 
that overweight and obese patients received adequate doses of 
protocol therapy. Assessment of chemotherapy dose delivery 
was based upon cycle 1 doxorubicin administration tested as a 
dichotomous variable, with adequate delivery defined as receipt 
of as at least 95% of the expected dose. Expected dose was cal-
culated according to the body surface area reported by the study 
site at the time of patient enrollment.
PAM50 subtype was assessed using paraffin-embedded 
archived tumor tissue for all patients from whom tissue was 
available. RNA extraction from either block punches or macro-
dissected slides was performed at Washington University 
Clinical Laboratory Improvement Amendment (CLIA) molecular 
laboratories using an isolation kit and procedures provided by 
NanoString Technologies, Inc., and expression profiles were gen-
erated on a Research Use Only (RUO) nCounter Analysis System 
and RUO PAM50 probe set. Raw data (RCC files) that passed sam-
ple and quality metrics were provided in a blinded fashion to 
NanoString Technologies for normalization and analysis with 
a proprietary PAM50 algorithm. Gene expression profiles were 
categorized using a four-level classifier: Luminal A, Luminal B, 
Basal-like, and HER2-enriched, based upon Pearson’s distance to 
centroids reestablished for the nCounter platform.
Statistical Analysis
Data collection and statistical analyses were conducted by the 
Alliance Statistics and Data Center. Descriptive statistics were 
used to summarize baseline BMI. Comparisons between patient 
and tumor characteristics and BMI categories were tested using 
the Mann-Whitney test and Pearson chi-squared test for con-
tinuous and categorical variables, respectively. The primary end-
point was recurrence-free survival (RFS) under the STEEP system 
(16), defined as time from study entry until first recurrence, 
whether local or distant, or death without recurrence. Patients 
who were alive and recurrence free were censored at the date of 
last status verification. Contralateral breast cancers and second 
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primary non-breast cancers were not considered failures; par-
ticipants continued to be followed for RFS. With 1909 patients 
and 552 RFS events anticipated, there was 90% power to observe 
a hazard ratio of 1.32 under a median split of BMI when using a 
two-sided alpha of 0.05 for testing. Overall survival (OS), defined 
as time from study entry until death because of any cause, was 
a secondary study endpoint. Distributions of RFS and OS were 
calculated using the Kaplan-Meier product limit method.
The relationship between BMI and RFS was first explored 
in a proportional hazards regression model using nonlin-
ear cubic spline functions knotted at evenly spaced quintiles 
(see Supplementary Figure  1, available online), and linear and 
Table 1. Patient characteristics by baseline body mass index
P*
BMI category
Total
Underweight
(<18.5 kg/m2)
Normal
(18.5–24.9 kg/m2)
Overweight
(25–29.9 kg/m2)
Obese
(≥30 kg/m2)
Characteristic No. (%) No. (%) No. (%) No. (%) No. (%)
Study patients 22 (1.1) 623 (32.6) 628 (32.9) 636 (33.3) 1909 (100)
Study patients 22 (100) 623 (100) 628 (100) 636 (100) 1909 (100)
Drug sequence .25
 Sequential 12 (54.5) 307 (49.3) 293 (46.7) 332 (52.2) 944 (49.4)
 Concurrent 10 (45.5) 316 (50.7) 335 (53.3) 304 (47.8) 965 (50.6)
Dose density .38
 3 weeks 9 (40.9) 328 (52.6) 307 (48.9) 311 (48.9) 955 (50.0)
 2 weeks 13 (59.1) 295 (47.4) 321 (51.1) 325 (51.1) 954 (50.0)
Age, y <.001†
 20–29 4 (18.2) 126 (20.2) 98 (15.6) 63 (9.9) 291 (15.2)
 30–39 8 (36.4) 241 (38.7) 199 (31.7) 216 (34.0) 664 (34.8)
 40–49 5 (22.7) 178 (28.6) 204 (32.5) 233 (36.6) 620 (32.5)
 50–59 4 (18.2) 65 (10.4) 107 (17.0) 109 (17.1) 285 (14.9)
 60–69 1 (4.5) 13 (2.1) 20 (3.3) 15 (2.4) 49 (2.6)
 (Median) (50) (48) (51) (51) (50)
Ethnicity <.001‡
 White 20 (90.9) 540 (86.7) 517 (82.3) 494 (77.7) 1571 (82.3)
 Hispanic 0 (0) 17 (2.7) 30 (4.8) 33 (5.2) 80 (4.2)
 African Amer 2 (9.1) 34 (5.5) 71 (11.3) 98 (15.4) 205 (10.7)
 Asian 0 (0) 20 (3.2) 6 (1.0) 2 (0.3) 28 (1.5)
 Other 0 (0) 11 (1.8) 4 (0.6) 8 (1.3) 23 (1.2)
 Not reported 0 (0) 1 (0.2) 0 (0) 1 (0.2) 2 (0.1)
Menopausal <.001
 Pre 10 (45.5) 364 (58.4) 304 (48.4) 272 (42.8) 950 (49.8)
 Post 12 (54.5) 259 (41.6) 324 (51.6) 364 (57.2) 959 (50.2)
Tumor size, cm .004
 At most 2 6 (27.3) 288 (46.2) 240 (38.2) 226 (35.5) 760 (39.8)
 >2 but ≤5 16 (72.7) 322 (51.7) 371 (59.1) 396 (62.3) 1105 (57.9)
 Missing 0 (0) 13 (2.1) 17 (2.7) 14 (2.2) 44 (2.3)
No. positive nodes .44
 1–3 13 (59.1) 394 (63.2) 369 (58.8) 364 (57.2) 1140 (59.7)
 4–9 7 (31.8) 171 (27.4) 184 (29.3) 185 (29.1) 547 (28.7)
 10+ 2 (9.1) 53 (8.5) 68 (10.8) 82 (12.9) 205 (10.7)
 Missing 0 (0) 5 (0.8) 7 (1.1) 5 (0.8) 17 (0.9)
ER status .71
 Negative 8 (36.5) 216 (34.7) 204 (32.5) 211 (33.2) 639 (33.5)
 Positive 14 (63.6) 400 (64.2) 412 (65.6) 410 (64.5) 1236 (64.7)
 Missing 0 (0) 7 (1.1) 12 (1.9) 15 (2.4) 34 (1.8)
PgR status .87
 Negative 11 (50.0) 255 (40.9) 260 (41.4) 260 (40.9) 786 (41.2)
 Positive 10 (45.5) 357 (57.3) 352 (56.1) 361 (56.8) 1080 (56.6)
 Missing 1 (4.5) 11 (1.8) 16 (2.5) 15 (2.4) 43 (2.3)
Tamoxifen use .30
 Yes 16 (72.7) 429 (68.9) 464 (73.9) 438 (68.9) 1347 (70.6)
 No 6 (27.3) 185 (29.7) 159 (25.3) 186 (29.2) 532 (27.9)
 Missing 0 (0) 9 (1.4) 5 (0.8) 12 (1.9) 26 (1.4)
* P value is from comparison of stated variable and body mass index category using a Pearson chi-squared test. Unless otherwise stated, comparisons are by specified 
categories. BMI = body mass index; ER = estrogen receptor; PgR = progestin receptor.
† Age as a continuous variable.
‡ Comparison of white vs all other ethnicities.
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nonlinear BMI components were assessed using Wald-type tests 
(17). Next, multivariable proportional hazards regression models 
(18) evaluated the adjusted hazard ratio of RFS (and OS) for a lin-
ear increase of pretreatment BMI when including study factors 
(sequence of chemotherapeutic regimen [sequential vs concur-
rent] and cycle length [q2-week vs q3-week]) as well as patient/
tumor characteristics of documented importance in early-stage 
breast cancer: estrogen receptor (ER) status (negative vs positive), 
tumor size (square root transformation), menopausal status (pre 
vs post) and number of positive lymph nodes (square root trans-
formation). PAM50-intrinsic subtypes were evaluated as a four-
level factor. Interactions between BMI and PAM50 subtype and 
between BMI and ER were tested in the multivariable model of 
RFS described above. The assumption of proportional hazards was 
evaluated using the methods from Grambsch and Therneau (19).
Adjusted hazard ratios from multivariable models are reported 
with 95% confidence intervals and Wald-type P values. A P value of 
less than .05 was considered statistically significant. All statistical 
inferences were performed using SAS v9.2 (Cary, NC) or R v3.1.1(20).
Results
Two thousand five individuals were enrolled in C9741, 1972 of 
whom initiated protocol treatment (see Supplementary Figure 2, 
available online). Primary study results have been published pre-
viously by Citron et al. (15). In brief, patients randomly assigned 
to every-two-week therapy experienced a statistically significant 
improvement in recurrence-free survival and overall survival as 
compared with those randomly assigned to every-three-week 
therapy (HR = 0.74, 95% CI = 0.59 to 0.93, P = .01 and HR = 0.69, 
95% CI = 0.50 to 0.93, P = .01 for RFS and OS, respectively). There 
was no difference in outcomes between patients randomly 
assigned to concurrent vs sequential therapy.
Baseline BMI was available for 1909 of 2005 patients. These 
patients comprise the study sample for the current analysis. Of 
these patients, 1272 had PAM50 subtyping results available and 
comprise the sample for the PAM50 subset analyses. Baseline 
characteristics of the 1909 patients for whom pretreatment BMI 
was available are presented in Table 1. Half of the participants were 
premenopausal, 64.7% had estrogen receptor–positive tumors, 
59.7% had one to three involved nodes, 57.9% had tumors between 
2 and 5 cm, and 70.6% took tamoxifen. Median BMI was 27.4 kg/m2 
(range 16.1–74.8); 1.1% of patients were underweight, 32.6% were 
normal weight, 32.9% were overweight, and 33.3% were obese.
Baseline BMI and Tumor and Host Characteristics
BMI was associated with tumor size (P  =  .004) and patients’ 
race, age, and menopausal status at registration (all P < .001). 
Overweight and obese women were more likely to be nonwhite 
(20.0% vs 14.3%) and postmenopausal (54.4% vs 41.4%) and more 
likely to have tumors bigger than 2 cm (63.1% vs 52.4%) com-
pared with normal and underweight women. There was no rela-
tionship between BMI and number of involved nodes. BMI was 
not associated with estrogen or progesterone receptor status.
In the subgroup with tissue available for the PAM50 assess-
ment (n = 1272), there was a moderate difference in the distribu-
tion of subtypes by BMI category (P = .03) (Table 2). The proportions 
of tumors that were Basal-like and HER2-enriched were gen-
erally similar across weight groups. In contrast, although the 
overall frequency of Luminal tumors was similar across weight 
groups, the proportion of Luminal tumors that were Luminal B 
was greater in obese women (52.2%) relative to overweight and 
normal weight women (44.7% and 37.9%, respectively).
BMI and Chemotherapy Dose Delivery
Dosing information was available for 1786 patients. Almost all 
patients received more than 95% of expected dose delivery for the 
first cycle of doxorubicin protocol therapy, with only 1.9% of patients 
receiving reduced doses of doxorubicin for the first cycle of treat-
ment. There was no difference between the proportion of patients 
who received reduced-dose therapy by BMI category, with 1% of nor-
mal weight, 2% of overweight, and 3% of obese individuals receiving 
reduced doses of therapy for the first treatment cycle (P = .22).
Baseline BMI and Cancer Outcomes
At a median follow up of 11  years (range  =  2–13  years), there 
were 619 RFS events and 543 deaths among the 1909 patients for 
whom baseline BMI was available. The univariate relationship 
between baseline BMI category and RFS is shown in Figure 1. In 
univariate analysis with spline regression models, a linear rela-
tionship between BMI and RFS was statistically significant (P < 
.04), while nonlinear components of the model did not reach 
nominal statistical significance (all Ps > .4) (Supplementary 
Figure 1, available online). This supported considering BMI as a 
linear term in the regression models. In multivariable analyses 
adjusted for number of involved lymph nodes, tumor size, estro-
gen receptor status, menopausal status of the patient, and treat-
ment arm, baseline BMI was a statistically significant predictor 
of RFS (P = .01) (Table 3). In this multivariable model, a five-unit 
increase in BMI corresponded to an 8% increase in risk of an RFS 
event (adjusted HR = 1.08, 95% CI = 1.02 to 1.14, P = 0.01).
Figure 1 also shows OS by BMI category. In multivariable anal-
yses adjusted for the variables detailed above (data not shown), 
baseline BMI was a predictor of OS, with a five-unit increase 
in BMI corresponding to an 8% increase in the risk of death 
Table 2. Baseline body mass index and distribution of PAM50 subtypes*
BMI category
Total
Underweight
(<18.5 kg/m2)
Normal
(18.5–24.9 kg/m2)
Overweight
(25–29.9 kg/m2)
Obese
(≥30 kg/m2)
Subtype No. (%) No. (%) No. (%) No. (%) No. (%)
PAM substudy patients 17 409 409 437 1272
Basal-like 5 (29.4) 101 (24.7) 73 (17.8) 105 (24.0) 284 (22.3)
HER2-enriched 4 (23.5) 81 (19.8) 83 (20.3) 83 (19.0) 251 (19.7)
Luminal A 3 (17.6) 141 (34.5) 140 (34.2) 119 (27.2) 403 (31.7)
Luminal B 5 (29.4) 86 (21.0) 113 (27.6) 130 (29.7) 334 (26.3)
* BMI = body mass index; HER2 = human epidermal growth factor receptor 2.
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(adjusted HR  =  1.08, 95% CI  =  1.01 to 1.14, P  =  .02). There was 
no interaction between cycle length and the prognostic value of 
baseline BMI on RFS (P = .41) or on OS (P = .27).
BMI and Outcomes by Estrogen Receptor Status 
and PAM50
Multivariable models adjusted for known prognostic factors (as 
detailed above) did not demonstrate an interaction between 
estrogen receptor status and BMI (linearly modeled) on recur-
rence-free (P =  .87) or overall survival (P =  .53). For both estro-
gen receptor–positive and estrogen receptor–negative patients, 
there was an identical increase in the risk of both relapse and 
death with increasing BMI.
An exploratory analysis of the prognostic value of baseline 
BMI and PAM50 was performed using a multivariable model 
adjusting for the factors described above. In the subset with 
PAM50 data, BMI remained a statistically significant prognostic 
Years from study entry
P
ro
po
rt
io
n 
re
cu
rr
en
ce
−f
re
e
0 2
A
B
4 6 8 10 12
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
< 18.5
18.5 − 24.9
25 − 29.9
30+
Number at risk
22 19 14 13 12 11 3
621 569 503 451 396 352 87
630 542 471 413 369 329 67
636 555 471 421 376 328 68
Events = 9
Events = 179
Events = 208
Events = 223
N = 22
N = 623
N = 628
N = 636
< 18.5
18.5 − 24.9
25 − 29.9
30+
Years from study entry
P
ro
po
rt
io
n 
su
rv
iv
ng
0 2 4 6 8 10 12
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
< 18.5
18.5 − 24.9
25 − 29.9
30+
Number at risk
22 19 16 15 15 13 3
623 602 546 494 436 382 102
628 589 526 450 405 354 85
636 601 530 465 408 351 75
Deaths = 7
Deaths = 151
Deaths = 184
Deaths = 201
N = 22
N = 623
N = 628
N = 636
< 18.5
18.5 − 24.9
25 − 29.9
30+
Figure 1. Recurrence-free (A) and overall (B) survival by body mass index. BMI = body mass index.
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factor, with a five-unit increase in BMI resulting in a hazard ratio 
of 1.12 (95% CI = 1.04 to 1.19, P = .01) (Figure 2). In the multivaria-
ble model, the interaction test between the prognostic effects of 
BMI and intrinsic subtype did not reach statistical significance (3 
df, P = .15). Within subgroups defined by PAM50, the unadjusted 
HR for each five-unit increase in BMI was highest at 1.23 (95% 
CI = 1.08 to 1.40) in Luminal A, lowest at 1.00 (95% CI = 0.87 to 
1.16) in Luminal B, 1.10 (95% CI = 0.97 to 1.26) in HER2 enriched, 
and 1.11 (95% CI = 0.97 to 1.28) in the Basal-like subgroup.
Discussion
In a population of women with early-stage breast cancer treated 
with optimal doses of adjuvant chemotherapy, obesity was an 
independent prognostic factor for both recurrence-free and over-
all survival. Each five-unit increase in BMI (for example, increas-
ing from a BMI of 22 mg/m2, which is in the normal range, to a 
BMI of 27 kg/m2, in the overweight range) was associated with an 
increase in the risk of cancer recurrence and death, or of death 
alone, of approximately 8%. Being underweight was also associ-
ated with poor prognosis, but these analyses were based on only 
a small number of patients; more work is needed to define the 
relationship between BMI and outcomes in underweight individ-
uals. Obese patients were more likely to have larger tumors and 
to be postmenopausal, but the distributions of tumor grade and 
tumor hormone receptor status were similar across weight cat-
egories. In contrast, PAM50 subtypes were distributed differently 
in obese and nonobese individuals, with Luminal B tumors being 
more common and Luminal A  tumors less common in obese 
individuals. Finally, exploratory analyses did not show an interac-
tion between molecular subtype by PAM50 and the relationship 
between increased BMI and RFS, suggesting that obesity related 
to poor clinical outcome regardless of tumor subtype.
Our data demonstrating an increased risk of cancer recur-
rence and mortality in obese individuals with early-stage breast 
cancer are consistent with numerous studies reporting a rela-
tionship between BMI and cancer outcomes. However, in contrast 
to some reports, we found that increased BMI was associated 
with an increased risk of breast cancer recurrence and mortality 
regardless of hormone receptor status. In addition, exploratory 
analyses of the relationship between BMI and outcome in groups 
defined by PAM50 subtype suggested that BMI predicted out-
comes in patients with Basal-like and HER2-enriched cancers, 
providing additional evidence that the relationship between 
body weight and breast cancer outcomes was not restricted to 
patients with hormone receptor–positive tumors.
Our study is one of the first to provide information regard-
ing the relationship between biologic subtype and BMI in a large 
group of patients with early-stage breast cancer. Although the 
distribution of hormone receptor–positive and –negative cancers 
did not differ by weight category, our findings suggest that obese 
patients may have a different distribution of Luminal tumors 
as compared with leaner individuals. The higher proportion of 
Luminal B tumors could contribute to the poor outcomes seen in 
obese individuals, given that these cancers are associated with 
a higher risk of cancer recurrence as compared with Luminal 
A tumors. This finding needs to be replicated in other studies, 
but suggests that the biology of the tumors that obese women 
develop might account, at least in part, for the relationship seen 
between obesity and outcomes in breast cancer. It is not clear 
how this finding will influence the potential benefits of weight 
loss after cancer diagnosis in obese women with breast cancer; 
randomized trials are needed to evaluate the impact of purpose-
ful weight loss on disease outcomes in women with early breast 
cancer overall and by biological subtype.
Our study has limitations that should be noted. Our sample size 
was relatively modest, and PAM50 data were only available for a 
subset of patients, limiting the power of our analyses; however, our 
dataset is larger than that included in any other report on the rela-
tionship between biologic subtype and BMI to date. These analyses 
should be viewed as hypothesis generating and require further val-
idation. Our analyses were also retrospective and not preplanned. 
Although we adjusted these analyses for many known prognostic 
factors, it is possible that other factors we have not accounted for 
could influence the relationship between BMI and prognosis. We 
also lacked information regarding adherence to endocrine therapy, 
Table 3. Observed effect of BMI on recurrence-free survival: results of multivariable proportional hazards model (n = 1845, 32% events)
Variable  HR comparison HR (95% CI) P*
BMI 5-unit increase 1.08 (1.02 to 1.14) .01
No. nodes† 1: 10 0.44 (0.37 to 0.52) <.001
Tumor size† 2 cm: 5 cm 0.72 (0.62 to 0.82) <.001
Menopause Post: pre 1.11 (0.94 to 1.31) .22
ER status Negative: positive 1.54 (1.31 to 1.82) <.001
Sequence Sequential: concurrent 1.05 (0.89 to 1.23) .57
Dose density q 3 wks: q 2 wks 1.21 (1.03 to 1.43) .02
* P values are from a Wald-type test in the multivariable proportional hazards model. BMI = body mass index; CI = confidence interval; ER = estrogen receptor; 
HR = hazard ratio.
† A square root transformation was used in analyses as performed in Citron et al. (2003).
PAM50 subset
Luminal A
Luminal B
HER2−enriched
Basal−like
N
1272
403
334
251
284
HR (95% CI)
1.12 (1.04 to 1.19)
1.23 (1.08 to 1.40)
1.00 (0.87 to 1.16)
1.10 (0.97 to 1.26)
1.11 (0.97 to 1.28)
Hazard ratio
0.50 0.75 1.00 1.25 1.50
Figure 2. Recurrence-free survival by body mass index (BMI) in PAM50 subtypes. Hazard ratios are for a five-unit increase in BMI and displayed with 95% confidence 
intervals. The area of the square is proportional to the precision of the estimate. CI = confidence interval; HR = hazard ratio.
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given that the trial focused on the impact of chemotherapy on dis-
ease outcomes. Finally, our patient population was largely white, 
and thus it is not clear how these findings relate to minority popu-
lations, who are often disproportionally affected by obesity. Further 
evaluation of the relationship between obesity and breast cancer 
outcomes is needed in these populations.
In conclusion, we found an increased risk of breast cancer 
recurrence and death in overweight and obese individuals with 
newly diagnosed breast cancer taking part in an adjuvant clinical 
trial of anthracycline and taxane-based chemotherapy. Obesity 
was linked to differences in the distribution of breast cancer 
subtypes, with more aggressive Luminal B cancers observed to 
be more prevalent in obese individuals, potentially contribut-
ing to the poor outcomes seen in this population. Finally, there 
was no interaction between tumor subtype and the relation-
ship between body weight and prognosis, suggesting that obe-
sity was predictive of poor outcomes across biological subtypes. 
More work is needed to validate our findings regarding biologic 
differences between cancers developed by obese and nonobese 
individuals, to elucidate the biologic mechanisms by which obe-
sity affects prognosis, and to determine whether weight loss 
after breast cancer diagnosis can alleviate the inferior prognosis 
experienced by obese individuals with breast cancer.
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